ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency
Arcaion / Pixabay

ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency

In early December 2020, mRNA medicines company Arcturus Therapeutics Holdings Inc. ("Arcturus") announced that the company begun dosing participants within its Phase 1b clinical trial. Within the trial, researchers will…

Continue Reading ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency
An Ornithine Transcarbamylase Deficiency Treatment Has Been Approved for Clinical Trials
Pixabay

An Ornithine Transcarbamylase Deficiency Treatment Has Been Approved for Clinical Trials

Ornithine transcarbamylase (OTC) deficiency is a disorder that can cause comas, seizures, and death, making it necessary for those affected to seek treatment. Arcturus Therapeutics aims to give those with…

Continue Reading An Ornithine Transcarbamylase Deficiency Treatment Has Been Approved for Clinical Trials
CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency
Source: Pixabay

CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency

Another successful partnership in the rare disease community has come to fruition, reports The Pharma Letter. Just this past week, CureVac and Arcturus Therapeutics will become a powerhouse together with…

Continue Reading CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency